Responses
Late-breaking abstracts
Clinical trials in-progress
798 Safety, tolerability, and immunogenicity of mRNA-4157 in combination with pembrolizumab in subjects with unresectable solid tumors (KEYNOTE-603): an update
Compose a Response to This Article
Other responses
No responses have been published for this article.